SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 270 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $201,000 | -13.7% | 2,690 | 0.0% | 0.05% | -16.4% |
| Q4 2020 | $233,000 | +8.9% | 2,690 | -9.4% | 0.06% | -16.7% |
| Q4 2019 | $214,000 | -58.7% | 2,970 | -19.6% | 0.07% | -54.8% |
| Q3 2019 | $518,000 | -23.5% | 3,696 | 0.0% | 0.15% | -37.1% |
| Q2 2019 | $677,000 | -48.6% | 3,696 | -55.4% | 0.23% | -50.6% |
| Q1 2019 | $1,317,000 | +66.1% | 8,281 | 0.0% | 0.47% | +86.5% |
| Q4 2018 | $793,000 | -32.2% | 8,281 | 0.0% | 0.25% | -29.2% |
| Q3 2018 | $1,170,000 | -9.7% | 8,281 | 0.0% | 0.36% | -27.2% |
| Q2 2018 | $1,296,000 | +26.2% | 8,281 | 0.0% | 0.49% | +26.4% |
| Q1 2018 | $1,027,000 | -52.4% | 8,281 | -50.0% | 0.39% | +13.2% |
| Q4 2017 | $2,157,000 | +224.4% | 16,562 | +100.0% | 0.34% | +31.0% |
| Q2 2017 | $665,000 | +12.9% | 8,281 | 0.0% | 0.26% | -0.8% |
| Q1 2017 | $589,000 | +39.2% | 8,281 | 0.0% | 0.26% | +17.4% |
| Q4 2016 | $423,000 | -28.2% | 8,281 | 0.0% | 0.22% | -18.2% |
| Q3 2014 | $589,000 | – | 8,281 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |